An Oxford-based biotech company developing “cutting-edge” cancer treatments
Enara Bio has raised €29M across 1 funding round from 3 investors, most recently a Series B round in Oct 2024. Based in Oxford, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-10-03 | Series B | €29M |
| Francis Crick Institute,M Ventures,Pfizer |
| View deal → |
